TheraRadar
← Back
Data updated: Jun 28, 2026

BEXIMCO PHARMS USA

Generics

BEXIMCO PHARMS USA is a generic drug manufacturer focused on Dermatology, Infectious Disease.

1991
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

BEXIMCO PHARMS USA's Key Drugs

BEXIMCO PHARMS USA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BEXIMCO PHARMS USA's Recent FDA Approvals

New NDA/BLA approvals for BEXIMCO PHARMS USA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BEXIMCO PHARMS USA's Therapeutic Areas

BEXIMCO PHARMS USA's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 50%
1 drugs
Infectious Disease 50%
1 drugs

BEXIMCO PHARMS USA's Top Competitors

BEXIMCO PHARMS USA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BEXIMCO PHARMS USA Pipeline Snapshot

Active clinical trials for BEXIMCO PHARMS USA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling